Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 5059-5066

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Iguchi, Eriko ^a   Takeda, Haruhiko ^a   Ohara, Yoshiaki ^a   Sakamoto, Azusa ^a   Hatamaru, Keiichi ^a   Saito, Sumio ^a   Nasu, Akihiro ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Radiofrequency ablation; Recurrence; Repeatability; Survival

Indexed keywords

SERUM ALBUMIN; SORAFENIB;

ABDOMINAL BLEEDING; ADULT; AGED; ARTERIOGRAPHY; ARTICLE; ASCITES; BILOMA; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOTHORAX; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMOTHORAX; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84872660484     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kudo M: Radiofrequency ablation for hepatocellular carcinoma: Updated review in 2010. Oncology 78: 113-124, 2010.
2. Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
3. Allgaier HP, Deibert P, Zuber I, Olschewski M and Blum HE: Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 353: 1676-1677, 1999.
4. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
5. Cho YK, Kim JK, Kim MY, Rhim H and Han JK: Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: 453-459, 2009.
6. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD and Wu GB: Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. Eur J Surg Oncol 38: 286-295, 2012.
7. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surgery 249: 195-202, 2009.
8. Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A and Miyazaki I: Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20: 295-301, 1994.
9. Lencioni: Locoregional treatment of hepatocellular carcinoma. Hepatology 52: 762-773, 2010.
10. Lin SM, Lin CJ, Lin CC, Hsu CW and Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54: 1151-1156, 2005.
11. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T and Omata M: A randomized controlled trial or radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130, 2005.
12. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE and Bartolozzi C: Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228: 235-240, 2003.
13. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Nasu A, Kita R, Kimura T, Arimoto A and Osaki Y: Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 11: 143, 2011.
14. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C and Rossi S: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47: 82-89, 2008.
15. Tiong L and Maddern GJ: Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 98: 1210-1224, 2011.
16. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS and Yoo BC: Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: Long-term results and prognostic factors in a large single-institution series. Eur Radiol 17: 684-692, 2007.
17. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, Silini EM, Dionigi P, Calliada F, Quaretti P and Tinelli C: Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: A long-term cohort study. Hepatology 53: 136-147, 2011.
18. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M and Seror O: Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50: 1475-1483, 2009.
19. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M and Koike K: Radiofrequency ablation for hepatocellular carcinoma: 10-Year outcome and prognostic factors. Am J Gastroenterol 107: 569-577, 2012.
20. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP and Chen MS: Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: A prospective randomized trial. Radiology 262: 689-700, 2012.
21. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M and Yamaoka Y; Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469, 2006.
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
23. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M and Makuuchi M; HCC Expert Panel of Japan Society of Hepatology: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29: 339-364, 2011.
24. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T and Kadoya M: Progression to hypervascular hepatocellular carcinoma: Correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225: 143-149, 2002.
25. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T and Osaki Y: Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 46: 1418-1426, 2011.
26. Sacks D, McClenny T, Cardella J and Lewis C: Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 14: S199-S202, 2003.
27. Izumi N: Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol 26(Suppl 1): 115-122, 2011.
28. Lautz HU, Selberg O, Körber J, Bürger M and Müller MJ: Protein-calorie malnutrition in liver cirrhosis. Clin Investig 70: 478-486, 1992.
29. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis: Nutritional status in cirrhosis. J Hepatology 21: 317-335, 1994.
30. Ishikawa T, Michitaka I, Kamimura H, Higuchi K, Kubota T, Seki K, Ohta H, Yoshida T and Kamimura T: Oral Branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 56: 1491-1495, 2009.